SIRT1 and Hepatic steatosis: We observed a significant increase of HSP72, PPARα and Sirt1 with amelioration of hepatic steatosis, particularly in the combined treatment group, suggesting that not only vildagliptin, but also valsartan may participate in activating this pathway.